Quick Summary
Silotrif D 8mg Tablet
Last updated on 23 Jun 2026 | 10:30 AM (IST)
₹375
MRP: ₹469.21
(You Save ₹94.21)
10 TABLET(s) IN A STRIP
Silotrif D 8mg Tablet
Salt Composition
DUTASTERIDE,SILODOSINMarketer
MSN LABORATORIES (INDIA)
20% OFF
₹375
MRP: ₹469.21
Inclusive of all taxes
20% Off
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Substitutes
Silochet D Tablet
TREBUCHET LIFES...
₹ 22.50/tablet
40% cheaper
Sido D Tablet
AMPS BIOTECH PV...
₹ 33.80/tablet
9% cheaper
Introduction to Silotrif D 8mg Tablet
Silotrif D 8mg Tablet is a combination of two active ingredients called Dutasteride and Silodosin, which help to relieve the symptoms caused by an enlarged prostate in adults. It is mainly used to treat benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Dutasteride and Silodosim belong to the family called 5-Alpha reductase inhibitors and Alpha-1 blockers. Taking this medication can help to reduce the problems like difficulty in urination, frequent urination, and other related symptoms. This medicine is specifically for men and should not be taken by women or children.
Silotrif D 8mg Tablet should not be consumed if you are allergic to Dutasteride, Silodosin, or any of its ingredients in the medication. Do not consume this medicine if you have severe liver or kidney problems. Notify your doctor if you have heart disease or if you notice breast lumps or nipple discharge. It is advised to use contraceptives to avoid the transfer of semen. Inform your doctor if you are taking this medicine during a PSA test because it can affect PSA blood tests for detecting prostate cancer.
Uses of Silotrif D 8mg Tablet
- Treatment of benign prostatic hyperplasia
Therapeutic Effects of Silotrif D 8mg Tablet
Silotrif D 8mg Tablet blocks the conversion of the hormone testosterone to dihydrotestosterone by blocking an enzyme called 5α-reductase in the genital region. This reduces the concentration of dihydrotestosterone in the blood and increases the urine flow rate.
Interaction of Silotrif D 8mg Tablet with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Silotrif D 8mg Tablet and can cause undesirable side effects.
More Information about Silotrif D 8mg Tablet
- Keep out of sight and reach of pets and children.
- Do not freeze the medicine.
- Do not store above 30°C.
- Always check the expiry date before consuming it.
How to consume Silotrif D 8mg Tablet
Take the Silotrif D 8mg Tablet as your physician advises. Usually, the tablets will be taken with or without food. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Safety Advice for Silotrif D 8mg Tablet
Breast Feeding
Silotrif D 8mg Tablet is not recommended for use in women. Consult your doctor for more information.
Alcohol
It is unsafe to consume alcohol while taking Silotrif D 8mg Tablet. Please speak with your physician.
Liver
Silotrif D 8mg Tablet should be used cautiously in patients with liver conditions. Before starting the treatment, inform your physician about pre-existing liver conditions.
Lungs
It is unknown whether Silotrif D 8mg Tablet is safe for patients with lung problems. Notify your physician if you have any lung disease before starting the treatment. Contact your doctor if you experience any lung-related symptoms.
Driving
Patients should be cautious about driving and operating machinery while taking Silotrif D 8mg Tablet. Contact your doctor for more information.
Pregnancy
Silotrif D 8mg Tablet is only for men and should not be used by women. Pregnant women or those who could become pregnant should not handle the medication if it leaks, as it can harm the baby. If there is any contact, wash the area with soap and water immediately.
Side Effects of Silotrif D 8mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious
- Skin rash
- Hives
- Swelling of face, eyelids, lips, arms, or legs
Common
- Low sperm count and movement
- Low sex drive
- Impotence
- Enlarged or painful breasts
Word of Advice
Before prescribing Silotrif D 8mg Tablet, your healthcare provider will assess for prostate problems, including cancer. Inform their doctor if you have plans for cataract surgery and about all the underlying medical conditions. Do not stop the medicine until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information.
FAQs about Silotrif D 8mg Tablet
Q1.
How to manage the side effects of Silotrif D 8mg Tablet?
To manage the side effects of Silotrif D 8mg Tablet, follow the prescribed dosage, and report side effects promptly. Stay hydrated, avoid alcohol and other medicine. Maintain a healthy lifestyle, and attend follow-up appointments.
Q2.
What are the side effects of Silotrif D 8mg Tablet?
Common side effects of Silotrif D 8mg Tablet include low sperm count and movement, low sex drive, impotence, and enlarged or painful breasts. It is crucial to consult your doctor for any concerns or persistent side effects.
Q3.
What should I do if I miss a dose of Silotrif D 8mg Tablet?
If you miss a tablet dose, take it as soon as possible. However, if it's close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose the Silotrif D 8mg Tablet.
Q4.
Why should women not consume Silotrif D 8mg Tablet?
Silotrif D 8mg Tablet combination medication is not for women as it is intended for the treatment of enlarged prostate in adult men. It can cause adverse effects and potential harm during pregnancy.
Q5.
Is Silotrif D 8mg Tablet harmful to patients with kidney conditions?
Patients with kidney disease should cautiously consume Silotrif D 8mg Tablet. Dose adjustment may be necessary. Inform your doctor about any kidney conditions you have.
Fact Box of Silotrif D 8mg Tablet
Molecule Name: Dutasteride + Silodosin
| Therapeutic class: Urologics |
Pharmacological class: 1. 5-Alpha reductase inhibitors 2. Alpha-1 blockers
| Indications: Treatment of Benign prostatic hyperplasia
|
References
- Kazuhisa Hagiwara et al., Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study, BioMed Research International, 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852328/pdf/BMRI2016-4975851.pdf
- J. Goddard, A.N. Turner, Kidney and Urinary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 461-523.
- Peter J. Snyder, Androgens and the Male Reproductive Tract, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition, 2018, 833-843.
- Rivopharm UK Ltd, Electronic Medicines Compendium (EMC), [Revised on March 2017] [Accessed on 23 June 2023], *Microsoft Word - uk-pl-clean (medicines.org.uk)
- Dailymed, [Accessed on 23 June 2023], DailyMed - SILODOSIN capsule (nih.gov)
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Vijayalakshmi N.
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 23 Jun 2026 | 10:30 AM (IST)
Want to know more?
Read Our Editorial Policy
